Fonte: European Journal Metabolism and Pharmacokinetics. Nome do evento: European Congress of Biopharmaceutics and Pharmacokinetics. Unidades: FCF, FCFRP
Assunto: FARMACOLOGIA CLÍNICA
ABNT
SANTOS, S R C J et al. Reduction of hepatic oxidative drug metabolizing enzyme activities and conjugation capacity in liver cirrhosis and shistosomiasis. European Journal Metabolism and Pharmacokinetics. Geneva: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. . Acesso em: 16 maio 2024. , 1996APA
Santos, S. R. C. J., Bertoline, M. A., Pereira, M. D., De Paula, M. A. S. A., Amosako, C., Donzella, H., & Lanchote, V. L. (1996). Reduction of hepatic oxidative drug metabolizing enzyme activities and conjugation capacity in liver cirrhosis and shistosomiasis. European Journal Metabolism and Pharmacokinetics. Geneva: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo.NLM
Santos SRCJ, Bertoline MA, Pereira MD, De Paula MASA, Amosako C, Donzella H, Lanchote VL. Reduction of hepatic oxidative drug metabolizing enzyme activities and conjugation capacity in liver cirrhosis and shistosomiasis. European Journal Metabolism and Pharmacokinetics. 1996 ;(spec.): 76.[citado 2024 maio 16 ]Vancouver
Santos SRCJ, Bertoline MA, Pereira MD, De Paula MASA, Amosako C, Donzella H, Lanchote VL. Reduction of hepatic oxidative drug metabolizing enzyme activities and conjugation capacity in liver cirrhosis and shistosomiasis. European Journal Metabolism and Pharmacokinetics. 1996 ;(spec.): 76.[citado 2024 maio 16 ]